Literature DB >> 9032334

Founder virus population related to route of virus transmission: a determinant of intrahost human immunodeficiency virus type 1 evolution?

V V Lukashov1, J Goudsmit.   

Abstract

We and others have shown that in individual human immunodeficiency virus type 1 (HIV-1) infection, the adaptive evolution of HIV-1 is influenced by host immune competence. In this study, we tested the hypothesis that in addition to selective forces operating within the host, transmission bottlenecks have an impact on HIV-1 intrahost evolution. Therefore, we studied the intrahost evolution of the V3 region of the external glycoprotein gp120 of HIV-1 during the 3- and 5-year periods following seroconversion after parenteral versus sexual (male-to-male) transmission in 41 participants of the Amsterdam prospective cohorts of homosexual men (n = 31) and intravenous drug users (IVDUs; n = 10) who were AIDS free and had comparable numbers of CD4+ cells. We observed that HIV-1 strains in homosexual men accumulated over 5 years more nonsynonymous substitutions within the V3 loop than HIV-1 strains in IVDUs as a result of lower rates of nonsynonymous evolution in both the initial 3-year period from seroconversion and the following 2-year period as well as a larger proportion of nonsynonymous back substitutions in IVDUs. The mean numbers of synonymous substitutions did not differ between the two risk groups. Since HIV-1 strains in IVDUs could be distinguished from the viruses of homosexual men based on several nucleotide substitutions of which the most conserved is a synonymous substitution at the tip of the V3 loop (GGC pattern), we studied whether the founder virus population itself has an impact on the intrahost evolution of HIV-1. The mean number of nonsynonymous substitutions accumulated over 5 years within the V3 loop was lower in 10 IVDUs infected by the HIV-1 strains with the GGC signature than in 4 IVDUs infected by HIV-1 strains lacking this pattern, while the mean numbers of synonymous substitutions were similar in the two groups.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9032334      PMCID: PMC191287     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

1.  Rapid and simple method for purification of nucleic acids.

Authors:  R Boom; C J Sol; M M Salimans; C L Jansen; P M Wertheim-van Dillen; J van der Noordaa
Journal:  J Clin Microbiol       Date:  1990-03       Impact factor: 5.948

2.  Coordinate and independent effects of heroin, cocaine, and alcohol abuse on T-cell E-rosette formation and antigenic marker expression.

Authors:  R M Donahoe; J K Nicholson; J J Madden; F Donahoe; D A Shafer; D Gordon; P Bokos; A Falek
Journal:  Clin Immunol Immunopathol       Date:  1986-11

3.  Immunologic abnormalities in heroin addiction.

Authors:  C V Wetli; T A Noto; A Fernandez-Carol
Journal:  South Med J       Date:  1974-02       Impact factor: 0.954

4.  Estimation of evolutionary distances between homologous nucleotide sequences.

Authors:  M Kimura
Journal:  Proc Natl Acad Sci U S A       Date:  1981-01       Impact factor: 11.205

5.  Human immunodeficiency virus type 1 RNA populations in faeces with higher homology to intestinal populations than to blood populations.

Authors:  L van der Hoek; C J Sol; F Snijders; J F Bartelsman; R Boom; J Goudsmit
Journal:  J Gen Virol       Date:  1996-10       Impact factor: 3.891

6.  Suggestive evidence for receptors for morphine and methionine-enkephalin on normal human blood T lymphocytes.

Authors:  J Wybran; T Appelboom; J P Famaey; A Govaerts
Journal:  J Immunol       Date:  1979-09       Impact factor: 5.422

7.  Alteration of T and null lymphocyte frequencies in the peripheral blood of human opiate addicts: in vivo evidence for opiate receptor sites on T lymphocytes.

Authors:  R J McDonough; J J Madden; A Falek; D A Shafer; M Pline; D Gordon; P Bokos; J C Kuehnle; J Mendelson
Journal:  J Immunol       Date:  1980-12       Impact factor: 5.422

8.  Thrombocytopenia and intravenous heroin use.

Authors:  W H Adams; R A Rufo; L Talarico; S L Silverman; M J Brauer
Journal:  Ann Intern Med       Date:  1978-08       Impact factor: 25.391

9.  Immunoglobulins in heroin users.

Authors:  R R Blanck; N Ream; M J Deegan
Journal:  Am J Epidemiol       Date:  1980-01       Impact factor: 4.897

10.  Opiate receptors on lymphocytes and platelets in man.

Authors:  J N Mehrishi; I H Mills
Journal:  Clin Immunol Immunopathol       Date:  1983-05
View more
  9 in total

1.  Viral evolution and epidemiology.

Authors:  Katrin Leitmeyer; Rebeca Rico-Hesse
Journal:  Curr Opin Infect Dis       Date:  1997-10       Impact factor: 4.915

2.  Reappearance of founder virus sequence in human immunodeficiency virus type 1-infected patients.

Authors:  A C Karlsson; H Gaines; M Sällberg; S Lindbäck; A Sönnerborg
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

3.  A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression.

Authors:  M E Quiñones-Mateu; S C Ball; A J Marozsan; V S Torre; J L Albright; G Vanham; G van Der Groen; R L Colebunders; E J Arts
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

4.  Molecular characterization of HCV 1b intra-familiar infection through three generations.

Authors:  C Argentini; S Dettori; L Loiacono; V Guadagnino; T Stroffolini; M Rapicetta
Journal:  Virus Genes       Date:  1999       Impact factor: 2.332

Review 5.  The impact of viral and host elements on HIV fitness and disease progression.

Authors:  Kenneth R Henry; Jan Weber; Miguel E Quiñones-Mateu; Eric J Arts
Journal:  Curr HIV/AIDS Rep       Date:  2007-02       Impact factor: 5.071

6.  Evolution of the human immunodeficiency virus type 1 subtype-specific V3 domain is confined to a sequence space with a fixed distance to the subtype consensus.

Authors:  V V Lukashov; J Goudsmit
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

7.  Human immunodeficiency virus type 1 (HIV-1) diversity at time of infection is not restricted to certain risk groups or specific HIV-1 subtypes.

Authors:  Manish Sagar; Erin Kirkegaard; E Michelle Long; Connie Celum; Susan Buchbinder; Eric S Daar; Julie Overbaugh
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

8.  Infectivity and replication capacity of drug-resistant human immunodeficiency virus type 1 variants isolated during primary infection.

Authors:  Viviana Simon; Neal Padte; Deya Murray; Jeroen Vanderhoeven; Terri Wrin; Neil Parkin; Michele Di Mascio; Martin Markowitz
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

9.  Unequal evolutionary rates in the human immunodeficiency virus type 1 (HIV-1) pandemic: the evolutionary rate of HIV-1 slows down when the epidemic rate increases.

Authors:  Irina Maljkovic Berry; Ruy Ribeiro; Moulik Kothari; Gayathri Athreya; Marcus Daniels; Ha Youn Lee; William Bruno; Thomas Leitner
Journal:  J Virol       Date:  2007-07-18       Impact factor: 5.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.